Ocata Therapeutics Inc fka OCAT

[rocky301]

Twaro and farvie,

Twaro,
"We have had a lot of interest in the company by institutional biotech/healthcare investors, many of which cannot buy stocks on the OTCBB or sub $1, $2, and $5 equities."

Yes, that e-mail was posted here prior.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61190236

The quote above is akin to saying if I had $100K in a bank savings account the bank will give me a much better interest rate than the $1000 I now have. Also note that quote was tied into the context of a RS. I am well aware of the "reasons" institutions are not loading up and have suggested in many posts here I did NOT expect it to happen contrary to what others here were saying. This is one of many posts that detail just that.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58314841

Yesterdays post only indicated I thought it would be more than the paltry 700K shares that it is. With the OS# where it is it would take 15MM shares to equal 1%. I have been a strong advocate of an uplist with institutional ownership being one of the many advantages.

farvie,
As I recall, almost three years ago, such was not the case for Geron, prior to their phase I?

Geron was a big board stock, not a penny stock trading at less than .20 with a boat load of shares....huge difference

I also understand the "timing" of an uplist. Had we made the move in January it would have been a rough road as trials have not even begun. The idea that ACT cleansed the books to be a good looking OTC:BB stock wasn't the plan or goal. I respect the opinions of some here who believe we can make it to a big board on our own with a $3-$4 share price and deep down I hope they are right, I for one do not believe we can. A $4.5-$6 Billion market cap is unrealistic,imo, on the OTC.

At some point in time when trials are underway and efficacy progression reports trickle in I would suggest the uplist will take place "not to alienate the bigger players" whom all stocks need and can make a huge difference. If we truly are "a leader in the field of regenerative medicine" as all PR's indicate, then a move is warranted where true recognition can be realized. I hope sooner than later we can trade in one cent increments and not 4 digits...:)

"We have had a lot of interest in the company by institutional biotech/ healthcare investors, many of which cannot buy stocks on the OTCBB or sub $1, $2, and $5 equities. Obviously, at some point in the future, if it is advantageous for us to do RS (and only if!), we would consider it, but in the meantime, we do not want to alienate our many shareholders. I think you can see that we are running this company for a big future, not for short term movements in the stock."